Research location
Cedarhurst
New York, United States
Advertisement
Research activity in Cedarhurst
New York, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 145 trials and 145 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Cedarhurst
145 linked trials · page 1 of 3A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With SchizophreniaNCT07615426 · 2026-03-02 · 1 site observation
RECRUITING
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive DisorderNCT07115329 · 2026-01-05 · 1 site observation
RECRUITING
Efficacy of NBI-1117568 in Preventing Relapse in Adults With SchizophreniaNCT07227818 · 2025-12-16 · 1 site observation
RECRUITING
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With SchizophreniaNCT07114874 · 2025-07-11 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)NCT07065240 · 2025-06-19 · 1 site observation
RECRUITING
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT06963021 · 2025-05-30 · 1 site observation
RECRUITING
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT06966401 · 2025-04-16 · 1 site observation
RECRUITING
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive DisorderNCT06547489 · 2025-02-03 · 1 site observation
RECRUITING
A Study to Evaluate BMS-986511 in Adults With Major Depressive DisorderNCT07772531 · 2026-10-30 · 1 site observation
NOT_YET_RECRUITING
A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With ObesityNCT07310901 · 2025-12-04 · 1 site observation
ACTIVE_NOT_RECRUITING
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)NCT07161700 · 2025-09-02 · 1 site observation
ENROLLING_BY_INVITATION
A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 DiabetesNCT07112872 · 2025-08-19 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityNCT07081958 · 2025-07-29 · 1 site observation
COMPLETED
Study to Evaluate Efficacy and Safety of Ropanicant in MDD PatientsNCT06836063 · 2025-07-15 · 1 site observation
COMPLETED
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of SchizophreniaNCT06791122 · 2025-01-23 · 1 site observation
COMPLETED
A Study to Test Different Doses of BI 1569912 in People With DepressionNCT06558344 · 2024-10-01 · 1 site observation
COMPLETED
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityNCT06525935 · 2024-08-16 · 1 site observation
COMPLETED
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)NCT06423781 · 2024-08-01 · 1 site observation
COMPLETED
Efficacy and Safety Study of BHV-7000 Monotherapy in Major DepressionNCT06419608 · 2024-05-28 · 1 site observation
COMPLETED
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive MedicineNCT06280235 · 2024-03-27 · 1 site observation
COMPLETED
Study to Assess the Safety and Effectiveness of NMRA-335140-501NCT06029439 · 2023-11-10 · 1 site observation
TERMINATED
Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06029426 · 2023-09-20 · 1 site observation
COMPLETED
Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDDNCT06011577 · 2023-08-17 · 1 site observation
TERMINATED
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of SchizophreniaNCT05838625 · 2023-03-31 · 1 site observation
COMPLETED
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With SchizophreniaNCT05443724 · 2022-09-01 · 1 site observation
TERMINATED
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive DisorderNCT05376150 · 2022-05-19 · 1 site observation
COMPLETED
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX StudyNCT05211947 · 2022-03-21 · 1 site observation
TERMINATED
Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With SchizophreniaNCT05182476 · 2021-12-07 · 1 site observation
TERMINATED
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for SchizophreniaNCT05110157 · 2021-11-29 · 1 site observation
COMPLETED
An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderNCT05061719 · 2021-10-08 · 1 site observation
COMPLETED
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)NCT04846881 · 2021-08-24 · 1 site observation
COMPLETED
Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderNCT04985942 · 2021-07-30 · 1 site observation
COMPLETED
A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive DisorderNCT04969510 · 2021-06-24 · 1 site observation
COMPLETED
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)NCT04855747 · 2021-03-30 · 1 site observation
TERMINATED
A Clinical Trial of PRAX-114 in Participants With Major Depressive DisorderNCT04832425 · 2021-03-30 · 1 site observation
COMPLETED
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)NCT04524403 · 2020-09-09 · 1 site observation
COMPLETED
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic TreatmentNCT04421456 · 2020-08-18 · 1 site observation
TERMINATED
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive DisorderNCT04285515 · 2020-02-27 · 1 site observation
COMPLETED
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With SchizophreniaNCT04158687 · 2019-11-26 · 1 site observation
COMPLETED
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.NCT04115319 · 2019-11-21 · 1 site observation
COMPLETED
A Study to Test if TV-46000 is Safe for Maintenance Treatment of SchizophreniaNCT03893825 · 2019-04-17 · 1 site observation
COMPLETED
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)NCT03745820 · 2018-11-15 · 1 site observation
COMPLETED
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With SchizophreniaNCT03593213 · 2018-07-30 · 1 site observation
TERMINATED
Zelquistinel in the Treatment of Major Depressive DisorderNCT03586427 · 2018-06-13 · 1 site observation
COMPLETED
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With SchizophreniaNCT03503318 · 2018-04-27 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive DisorderNCT03446846 · 2018-03-30 · 1 site observation
COMPLETED
This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 MonthsNCT03351244 · 2017-12-07 · 1 site observation
TERMINATED
Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaNCT03121586 · 2017-01-01 · 1 site observation
TERMINATED
A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With AntipsychoticsNCT02953639 · 2016-11-30 · 1 site observation
COMPLETED
Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)NCT02970292 · 2016-10-26 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.